In cultured human HSCs, sodium valproate, a broad class I and II HDAC inhibitor also used in the clinic to treat a variety of neurological disorders, demonstrated antifibrotic properties by inhibiting the expression of Col1a1 and TGFβ1 without causing toxic effects [97]. Here, HDAC9 is linked to nervous system disorder.